NEWS
IMAGEBIOPSY LAB AND RADIOBOTICS JOIN FORCES TO ADVANCE MUSCULOSKELETAL IMAGING WITH AI
ImageBiopsy Lab and Radiobotics have teamed up to advance the use of Artificial Intelligence ( AI ) supported disease diagnostics for musculoskeletal ( MSK ), orthopaedic and trauma use-cases in the DACH region .
Globally , musculoskeletal conditions affect a larger population than circulatory or respiratory disorders . Despite this , diagnostic methods often remain rooted in outdated practices , relying on manual interpretation of X-rays and MRI images . These subjective and time-intensive techniques lack standardisation and depend on practitioner expertise . imaging , encompassing measurement , scoring and fracture detection workflow .
Dr Richard Ljuhar , CEO and Co-founder of ImageBiopsy Lab , said : " Before even considering the use of AI , it ' s crucial to grasp physicians ' diagnostic workflow and needs . For this purpose , we ' ve closely collaborated with leading MSK radiologists , orthopaedics and traumatologists over the past years . We see Radiobotics as the logical partner to offer best in class solutions for MSK conditions diagnostics , from measurements and scoring to fracture detection . Our collaboration marks the next AI-powered workflow integration phase .”
Mads Jarner , CEO and Co-founder of Radiobotics , added : " As MSK AI solutions gain traction in clinical workflows , providing clinics with integrated and comprehensive options becomes vital . We ' re thrilled to collaborate with ImageBiopsy Lab to facilitate access to our market-leading solutions .”
Despite a growing number of MSK-specific solutions , users lack a holistic answer for diverse diagnostic needs . With their collaboration , ImageBiopsy Lab and Radiobotics ( both with MDR and FDA clearances ) will merge their expertise and provide a single , comprehensive solution for MSK
ZSCALER PARTNERS WITH IMPRIVATA AND CROWDSTRIKE FOR ZERO TRUST SECURITY FOR HEALTHCARE ORGANISATIONS
Zscaler , a leader in cloud security , has announced that it has teamed up with CrowdStrike and Imprivata to deliver a Zero Trust cybersecurity solution from device to cloud that ’ s custommade for medical institutions . The new Zscaler integration with the Imprivata Digital Identity Platform will provide visibility , threat protection and traceability for end-to-end , multiuser , shared device access control that are required for organisations to meet regulatory requirements , including HIPAA and HITECH .
Through the new Zscaler integration with Imprivata , Zscaler is able to take Imprivata context and leverage the existing integration with CrowdStrike Falcon Zero Trust Assessment ( ZTA ) score to control access to applications with adaptive , risk-based policies .
As ransomware targeting healthcare organisations increases , more advanced cybersecurity is needed to protect sensitive patient data and maintain uninterrupted operations for the continuous delivery of lifecritical medical services . With this new integration , users of the Zscaler Zero Trust Exchange platform , Imprivata OneSign and the CrowdStrike Falcon platform will be able to more effectively adopt a Zero Trust architecture that offers granular access management , threat protection and traceability capabilities to better protect against ransomware .
Hospitals and healthcare organisations face a unique security and identity challenge . With shared workstations among staff , they must determine how they can distinguish who is doing what on which device and enforce access control policies and threat protections based on both the user who logged in at the time and the device ' s posture . They also need to keep track of all user activity with logs indicating their actions for traceability and compliance requirements .
www . intelligenthealth . tech 7